Articles and Videos
Loading...
June 14, 2022
Scientific study on the biological activity of rare cannabinoids and their potential role on skin conditions published in peer-reviewed article
A peer-reviewed scientific study entitled “Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes” has been published in the International Journal of Molecular Sciences....
May 17, 2022
The Dales Report: InMed Pharmaceuticals: Commercializing The Development Of Rare Cannabinoids For The Wellness Market
Shadd Dales of The Dales Report interviews InMed CEO, Eric A. Adams, about the rare cannabinoid market and being able to manufacture rare cannabinoids like...
April 28, 2022
Edison: Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids
InMed featured in this article about the different cannabinoid manufacturing technologies that are shaping the industry. The article by Edison also talks about the cannabinoid...
April 28, 2022
Fly exclusive interview with CEO Eric Adams
Leading digital financial news publisher "The Fly" gets an update on the launch of InMed's rare cannabinoid products and progress of our programs from CEO Eric A....
April 11, 2022
Empowered Patient Podcast: Manufacturing Bioidentical Rare Cannabinoids to Treat Glaucoma and Rare Skin Disease with Eric Adams InMed Pharmaceuticals
Empowered Patient Podcast Host Karen Jagoda speaks with InMed CEO Eric A. Adams about the company's cannabinol programs in glaucoma and epidermolysis bullosa. Excerpt: Eric...
April 6, 2022
Fireside Chat with Roth Capital: InMed’s CEO, Eric A. Adams Sits Down with Roth Analyst Scott Henry
At the 2022 Roth Conference in California, InMed's CEO, Eric A. Adams, sat down with Roth Capital Analyst Scott R. Henry in a fireside chat....